Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Eli Lilly and Company    LLY

News SummaryMost relevantAll newsSector newsTweets

Eli Lilly and : Elanco, Aratana Announce Positive Opinion on GALLIPRANT® (grapiprant tablets) in Europe

share with twitter share with LinkedIn share with facebook
share via e-mail
11/10/2017 | 05:33pm CET

LEAWOOD, Kan., Nov. 10, 2017 /PRNewswire/ -- Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY) and Aratana Therapeutics, Inc. (NASDAQ: PETX), today announced the European Medicine Agency's (EMA) Committee for Medicinal Products for Veterinary Use (CVMP) adopted a positive opinion to recommend the marketing authorization of GALLIPRANT(®) (grapiprant tablets) in the European Union. Following the positive opinion, the European Commission will complete the regulatory process for a final decision on the Marketing Authorisation in early 2018.

Galliprant is a first-in-class veterinary medicine that will be indicated for the treatment of pain associated with mild to moderate osteoarthritis in dogs. Grapiprant, the active ingredient in Galliprant, is a non-steroidal non-cyclooxygenase inhibiting anti-inflammatory drug. Elanco has exclusive rights to develop, manufacture, market and commercialize Galliprant globally, and it co-promotes the product with Aratana in the United States.

About Elanco Animal Health
Elanco provides comprehensive products and knowledge services to improve animal health and food-animal production in more than 70 countries around the world. We value innovation, both in scientific research and daily operations, and strive to cultivate a collaborative work environment for more than 6,500 employees worldwide. Together with our customers, we are committed to raising awareness about global food security, and celebrating and supporting the human-animal bond. Founded in 1954, Elanco is a division of Eli Lilly and Company. Our worldwide headquarters and research facilities are located in Greenfield, Indiana (U.S.). Visit us at www.elanco.com or www.elancoeurope.com.

About Aratana Therapeutics
Aratana Therapeutics is a pet therapeutics company focused on licensing, developing and commercializing innovative therapeutics for dogs and cats. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to dogs and cats in a capital and time efficient manner. The company's pipeline includes therapeutic candidates for the potential treatment of pain, inappetence, viral diseases, allergy, cancer and other serious medical conditions. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets. For more information, please visit www.aratana.com.

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Galliprant, and reflects Lilly, Elanco's and Aratana's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there can be no guarantee that Galliprant will be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's and Aratana's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission, respectively. Except as required by law, Elanco and Aratana undertakes no duty to update forward-looking statements to reflect events after the date of this release.

Media Contacts
Karin Gerbens
[email protected]
+32 476 978 467

Rachel Reiff
[email protected]
+1 (913) 353-1050

View original content:http://www.prnewswire.com/news-releases/elanco-aratana-announce-positive-opinion-on-galliprant-grapiprant-tablets-in-europe-300553682.html

SOURCE Aratana Therapeutics, Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
11/17 ELI LILLY AND : Lilly to Participate in Evercore ISI 2017 Biopharma Catalyst/Dee..
11/16 ELI LILLY AND : New Data on FORTEO® teriparatide injection Showed Reduced Risk f..
11/16 ELI LILLY AND : Trademark Application for "ZENEFOST" Filed by Eli Lilly
11/16 ELI LILLY AND : Trademark Application for "T" Filed
11/16 ELI LILLY AND : Boehringer Ingelheim - Jardiance reduced risk of cardiovascular ..
11/14 ELI LILLY AND : National Community Pharmacists Association Issues Statement on T..
11/14 ELI LILLY AND : Yes to failing forward
11/14DJELI LILLY AND : Drug Prices Rose at Lilly -- WSJ
11/14 ELI LILLY AND : Jardiance® reduced risk of cardiovascular death in adults with t..
11/14 ELI LILLY AND COMPANY : ex-dividend day
More news
News from SeekingAlpha
11/17 Denali Therapeutics Files To Raise $100 Million IPO
11/17 Celldex launches mid-stage study of CDX-3379 in head and neck cancer
11/17 NOVO NORDISK : Q3 2017 Results Show Strong Future Potential
11/15 FDA OKs expanded use of AstraZeneca's breast cancer med Faslodex
11/14 YOUR DAILY PHARMA SCOOP : Heron Undervalued, Theravance Submits NDA, Nektar Cont..